A Review on the Design, Synthesis, and Structure-activity Relationships of Benzothiazole Derivatives against Hypoxic Tumors

dc.authoridAyaz, Furkan/0000-0003-0271-0594
dc.authoridNural, Yahya/0000-0002-5986-8248
dc.authorwosidAyaz, Lokman/K-6716-2013
dc.authorwosidAyaz, Furkan/HKE-5168-2023
dc.authorwosidNural, Yahya/K-1798-2015
dc.contributor.authorKurt, Akif Hakan
dc.contributor.authorAyaz, Lokman
dc.contributor.authorAyaz, Furkan
dc.contributor.authorSeferoglu, Zeynel
dc.contributor.authorNural, Yahya
dc.date.accessioned2024-06-12T10:51:55Z
dc.date.available2024-06-12T10:51:55Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThere has been a growing body of studies on benzothiazoles and benzothiazole derivatives as strong and effective anti-tumor agents against lung, liver, pancreas, breast, and brain tumors. Due to the highly proliferative nature of the tumor cells, the oxygen levels get lower than that of normal tissues in the tumor microenvironment. This situation is called hypoxia and has been associated with increased ability for carcinogenesis. For the drug design and development strategies, the hypoxic nature of the tumor tissues has been exploited more aggressively. Hypoxia itself acts as a signal initiating system to activate the pathways that eventually lead to the spread of the tumor cells into the different tissues, increases the rate of DNA damage, and eventually ends up with more mutation levels that may increase the drug resistance. As one of the major mediators of hypoxic response, hypoxia-inducible factors (HIFs) have been shown to activate angiogenesis, metastasis, apoptosis resistance, and many other protumorigenic responses in cancer development. In the current review, we will be discussing the design, synthesis, and structure-activity relationships of benzothiazole derivatives against hypoxic tumors such as lung, liver, pancreas, breast, and brain as potential anti-cancer drug candidates. The focus points of the study will be the biology behind carcinogenesis and how hypoxia contributes to the process, recent studies on benzothiazole and its derivatives as anti-cancer agents against hypoxic cancers, conclusions, and future perspectives. We believe that this review will be useful for researchers in the field of drug design during their studies to generate novel benzothiazole-containing hybrids against hypoxic tumors with higher efficacies.en_US
dc.identifier.doi10.2174/1570179419666220330001036
dc.identifier.endpage796en_US
dc.identifier.issn1570-1794
dc.identifier.issn1875-6271
dc.identifier.issue7en_US
dc.identifier.pmid35352663en_US
dc.identifier.scopus2-s2.0-85137167860en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage772en_US
dc.identifier.urihttps://doi.org/10.2174/1570179419666220330001036
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18534
dc.identifier.volume19en_US
dc.identifier.wosWOS:000851374900002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Organic Synthesisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-Cancer Activityen_US
dc.subjectBenzothiazoleen_US
dc.subjectHeterocyclic Compoundsen_US
dc.subjectHypoxiaen_US
dc.subjectOrganic Synthesisen_US
dc.subjectBrain Tumorsen_US
dc.subjectEndothelial Growth-Factoren_US
dc.subjectPas Domain Protein-1en_US
dc.subjectInducible Factor-Ien_US
dc.subjectBiological Evaluationen_US
dc.subjectGene-Expressionen_US
dc.subjectCancer Progressionen_US
dc.subjectCell-Proliferationen_US
dc.subjectUp-Regulationen_US
dc.subjectApoptosisen_US
dc.subjectAngiogenesisen_US
dc.titleA Review on the Design, Synthesis, and Structure-activity Relationships of Benzothiazole Derivatives against Hypoxic Tumorsen_US
dc.typeReview Articleen_US

Dosyalar